초록접수 현황
| 15F-118 | 포럼 발표 |
The Clinical Implication of Death Domain-associated Protein(DAXX) Expression in Esophageal Squamous Cell Carcinoma
박억숭², 조성래¹, 박성달¹, 김종인¹, 조성호¹, 이해영¹, 김현수¹, 문정민¹, 이세준¹, 장희경³
고신대학교 의과대학 복음병원 흉부외과학교실¹, 해운대 부민병원 흉부외과², 고신대학교 의과대학 복음병원 병리학교실³
Background : The function of Death Domain-associated Protein (DAXX), originally identified as a pro-apoptotic protein and has been expanded to be either a pro-apoptotic or an anti-apoptotic factor with chromatin remodeler, depending on the cell type and context. However, the role of DAXX in cancer is still debatable. This study made an attempt to evaluate DAXX expression and its clinical implication in the squamous cell carcinoma of esophagus to provide the basis for clinical feasibility of DAXX as biologic marker.
Methods : Immunohistochemical analysis was made on the paraffin-embedded tissues of 60 cases of esophageal squamous carcinoma which could provide the data for survival analysis. The immune reaction with more than 10% of tumor cells was interpretated as positive. Positive reaction was classified as 'with 11-50% of tumor cells' and 'with more than 51% of tumor cells'.The correlation of the expression with survival and clinical prognosticators were analyzed.
Results : Forty-three of 60 cases (71.7%) showed nuclear strong DAXX expression, among which 19 cases showed positive reaction (31.7%) with 11-50% of tumor cells and 24 cases (40.0%) with more than 51% of tumor cells. Negative reaction was in 17cases (28.3%). These patterns of immunostaining was significantly associated with N-stage(p=0.005), and AJCC stages(p=0.001), while overall survival showed no significant difference.
There were no correlation among age, gender, and T-stage with this expression. However, in stage IIB(p=0.046) and IV (p=0.014), DAXX expression is significant correlation with survival.
Conclusion : This investigation points out that the upregulation of DAXX was found in esophageal cancer with 71.7% of expression rate and DAXX immunostaining could be used in clinical practice for predicting aggressive tumor with lymph node metastasis and advanced stage, especially in stage IIB and IV.
Methods : Immunohistochemical analysis was made on the paraffin-embedded tissues of 60 cases of esophageal squamous carcinoma which could provide the data for survival analysis. The immune reaction with more than 10% of tumor cells was interpretated as positive. Positive reaction was classified as 'with 11-50% of tumor cells' and 'with more than 51% of tumor cells'.The correlation of the expression with survival and clinical prognosticators were analyzed.
Results : Forty-three of 60 cases (71.7%) showed nuclear strong DAXX expression, among which 19 cases showed positive reaction (31.7%) with 11-50% of tumor cells and 24 cases (40.0%) with more than 51% of tumor cells. Negative reaction was in 17cases (28.3%). These patterns of immunostaining was significantly associated with N-stage(p=0.005), and AJCC stages(p=0.001), while overall survival showed no significant difference.
There were no correlation among age, gender, and T-stage with this expression. However, in stage IIB(p=0.046) and IV (p=0.014), DAXX expression is significant correlation with survival.
Conclusion : This investigation points out that the upregulation of DAXX was found in esophageal cancer with 71.7% of expression rate and DAXX immunostaining could be used in clinical practice for predicting aggressive tumor with lymph node metastasis and advanced stage, especially in stage IIB and IV.
책임저자: 조성래
고신대학교 의과대학 복음병원 흉부외과학교실
연락처 : 김현수, Tel: 051-990-6466 , E-mail : redgrit@naver.com
